Literatura académica sobre el tema "Monoclonal antibody, immunocytokine, immunotherapy"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Monoclonal antibody, immunocytokine, immunotherapy".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Monoclonal antibody, immunocytokine, immunotherapy"
Singh, Harjeet, Lisa Marie A. Serrano, Simon Olivares, Michael Jensen, George McNamara, David Colcher, Andrew Raubitschek y Laurence J. N. Cooper. "Combining Immunocytokine with Adoptive Immunotherapy To Treat B-Lineage Lymphomas." Blood 106, n.º 11 (16 de noviembre de 2005): 343. http://dx.doi.org/10.1182/blood.v106.11.343.343.
Texto completoAiken, Taylor, Julie Voeller, Amy Erbe, Alexander Rakhmilevich y Paul Sondel. "458 Antitumor mechanisms of local radiation and combination immunotherapy in an immunologically cold model of neuroblastoma". Journal for ImmunoTherapy of Cancer 8, Suppl 3 (noviembre de 2020): A486. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0458.
Texto completoAlderson, Kory L. y Paul M. Sondel. "Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity". Journal of Biomedicine and Biotechnology 2011 (2011): 1–7. http://dx.doi.org/10.1155/2011/379123.
Texto completoAiken, Taylor J., David Komjathy, Mat Rodriguez, Arika Feils, Stephen D. Gillies, Amy K. Erbe, Alexander L. Rakhmilevich y Paul M. Sondel. "Short-course neoadjuvant intratumoral immunotherapy establishes immunologic memory in murine melanoma." Journal of Clinical Oncology 39, n.º 15_suppl (20 de mayo de 2021): e21561-e21561. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e21561.
Texto completoSchliemann, Christoph, Niklas Börschel, Christian Schwöppe, Rüdiger Liersch, Torsten Kessler, Martin Dreyling, Wolfram Klapper et al. "Targeting Interleukin-2 to the Neovasculature Potentiates Rituximab‘s Activity Against Mantle Cell Lymphoma in Mice". Blood 120, n.º 21 (16 de noviembre de 2012): 3716. http://dx.doi.org/10.1182/blood.v120.21.3716.3716.
Texto completoNiglio, Scot Anthony, Daniel da Motta Girardi, Lisa M. Cordes, Lisa Ley, Marissa Mallek, Olena Sierra Ortiz, Jacqueline Cadena et al. "A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies." Journal of Clinical Oncology 39, n.º 15_suppl (20 de mayo de 2021): TPS4599. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.tps4599.
Texto completoBerdel, Andrew F., Christoph Rollig, Martin Wermke, Linus Angenendt, Leo Ruhnke, Jan-Henrik Mikesch, Teresa Hemmerle et al. "A Phase I Trial of the Antibody-Cytokine Fusion Protein F16IL2 in Combination with Anti-CD33 Immunotherapy for Posttransplant AML Relapse". Blood 138, Supplement 1 (5 de noviembre de 2021): 2345. http://dx.doi.org/10.1182/blood-2021-145859.
Texto completoPelegrin, Mireia, Laurent Gros, Hanna Dreja y Marc Piechaczyk. "Monoclonal Antibody-based Genetic Immunotherapy". Current Gene Therapy 4, n.º 3 (1 de septiembre de 2004): 347–56. http://dx.doi.org/10.2174/1566523043346246.
Texto completoSchuster, James M. y Darell D. Bigner. "Immunotherapy and monoclonal antibody therapies". Current Opinion in Oncology 4, n.º 3 (junio de 1992): 547–52. http://dx.doi.org/10.1097/00001622-199206000-00020.
Texto completoMehra, NarinderK. "Antibody therapy: Substitution-immunomodulation -monoclonal immunotherapy". Indian Journal of Medical Research 149, n.º 4 (2019): 563. http://dx.doi.org/10.4103/ijmr.ijmr_2198_18.
Texto completoTesis sobre el tema "Monoclonal antibody, immunocytokine, immunotherapy"
Nadal, Lisa. "Isolation and validation of novel monoclonal antibodies targeting the tumor microenvironment for the selective delivery of cytokines payloads". Doctoral thesis, Università degli studi di Trento, 2021. http://hdl.handle.net/11572/323258.
Texto completoNicholson, Stephen. "Immune responses following monoclonal antibody therapy of ovarian cancer". Thesis, Imperial College London, 2000. http://hdl.handle.net/10044/1/8395.
Texto completoMehta, Payal. "Molecular Analysis of Regulation of Macrophage Fcγ Receptor Function: Implications for Tumor Immunotherapy". The Ohio State University, 2011. http://rave.ohiolink.edu/etdc/view?acc_num=osu1313606589.
Texto completoGustafsson, Liljefors Maria. "Immunotherapy with the anti-EpCAM monoclonal antibody and cytokines in patients with colorectal cancer : a clinical and experimental study /". Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-499-6/.
Texto completoTurrini, Riccardo. "Targeting BARF1 for the therapeutic control of EBV-associated malignancies". Doctoral thesis, Università degli studi di Padova, 2010. http://hdl.handle.net/11577/3427092.
Texto completoIl virus di Epstein-Barr è un γ-herpesvirus che infetta preferenzialmente i linfociti B umani. Si stima che il 95% della popolazione mondiale sia infettata, ma normalmente tale infezione avviene nell’infanzia ed è asintomatica. Oltre ad essere l'agente causale di una malattia linfoproliferativa autolimitante, la mononucleosi infettiva, la presenza del virus è associata ad alcune neoplasie umane, caratterizzate da diversi pattern di espressione genetica. Alcune delle neoplasie EBV-associate sono il linfoma di Burkitt (BL) e alcune forme di carcinoma gastrico (GC), il linfoma di Hodgkin (HL) e il carcinoma nasofaringeo (NPC), e infine le malattie linfoproliferative post-trapianto (PTLD). Oltre ai geni di latenza, è nota l’espressione di diversi RNA non poliadenilati (EBER) e, soprattutto nei casi di NPC e di GC, l’espressione da parte delle cellule infettate di una proteina transmembrana del ciclo litico, BARF1. BARF1 è una proteina di 221 aminoacidi, con una porzione transmembrana al C-terminale. Solo recentemente ne è stato dimostrato il ruolo trasformante ed immortalizzante in cellule umane. Inoltre, il dominio extracellulare può essere tagliato, ed è in grado di agire in modo paracrino come fattore di crescita per le cellule adiacenti, possedendo infatti attività mitogena. In generale, tuttavia, le attività mitogene e mutagene non sono state ancora completamente elucidate, ma l’importanza di questa proteina nei pathway di progressione neoplastica e la sua espressione unicamente nelle cellule infettate (o in quelle che ne legano la forma secreta) la rendono un ottimo candidato come bersaglio per un approccio terapeutico delle neoplasie EBV-correlate. Esistono diversi orientamenti terapeutici nei confronti delle neoplasie EBV-relate; alcune strategie prevedono la riduzione del regime di immunosoppressione, soprattutto per il trattamento di PTLD, la somministrazione di farmaci antivirali, la terapia genica, l’uso di chemioterapici e approcci di immunoterapia. L’uso di linfociti T citotossici (CTL) autologhi o da donatori compatibili si è dimostrata efficace e generalmente priva di effetti collaterali, soprattutto in pazienti affetti da PTLD. Un altro aspetto dell’immunoterapia prevede l’utilizzo di anticorpi monoclonali (mAb), come già dimostrato in ambito clinico dall'utilizzo di rituximab. In questo progetto di Dottorato viene descritta la generazione e la valutazione in vitro di diversi anticorpi monoclonali specifici per BARF1. Inoltre, una volta dimostratane l'attività su colture cellulari in vitro, si è traslato l'approccio ad alcuni modelli pre-clinici sfruttando topi immunodeficienti portatori di tumore EBV-positivo. Anche in questi esperimenti è stato possibile dimostrare l'efficacia terapeutica degli anticorpi prodotti. Da un lato, l’utilizzo di mAb sia nella diagnosi che nella cura di neoplasie sta assumendo un’importanza crescente in ambito clinico, grazie alla specificità di azione di queste molecole e alla loro relativa facilità d’uso, soprattutto se paragonati all’immunoterapia cellulare adottiva. Dall’altro, BARF1, benchè non ne siano ancora state completamente studiate le funzioni e le interconnessioni con altre molecole o cellule, è sicuramente un target promettente per i tumori EBV-relati, in quanto, nonostante sia una proteina espressa durante il ciclo litico, è presente soprattutto nei casi di NPC e di GC, e possiede importanti funzioni trasformanti, anche con azione paracrina.
RIZZUTO, MARIA ANTONIETTA. "Exploiting Nanotechnology to Improve Cancer Immunotherapy and Overcome Biological Barriers". Doctoral thesis, Università degli Studi di Milano-Bicocca, 2019. http://hdl.handle.net/10281/241065.
Texto completoThe use of therapeutic monoclonal antibodies (mAbs) has revolutionized cancer treatment. During the last decades, mAbs became very appealing also for nanotechnology. Indeed, they have been exploited as targeting moieties for nanoparticles, thanks to their high binding efficacy and target selectivity. However, the functionalization of NPs with mAbs is usually performed with the aim to ameliorate targeting, rather than to overcome mAbs limitations. Moreover, the therapeutic implications of nanoconjugation are generally poorly considered. In this thesis, I focused on the study of cancers with no efficient therapies available, such as brain cancers and triple negative breast cancer (TNBC), with the final goal to exploit nanoparticle (NP) conjugation as a tool to improve antibody-based therapies. In particular my work aimed at increasing the spectrum of action of already existing mAbs, making them suitable for new applications, either as the whole protein or as fragments. In Chapter 1, I used a recombinant human ferritin (HFn) as nanovector to promote mAbs permeation across the BBB to activate the ADCC response against brain cancer. Glioblastoma and HER2+ metastatic breast cancer were selected as brain tumor models. HFn was used as delivery system thanks to the ability to cross the BBB upon interaction with its receptor. Then, cetuximab or trastuzumab were linked to HFn and the maintenance of the cytotoxic activity of NPs was confirmed by in vitro assays. Next, we tested the ability of HFn- mAb to cross an in vitro model of BBB. Results showed that HFn-mAb proved to be effective in BBB crossing and that, after permeation, mAbs retained their biological activity against the targets, as assessed by MTS and ADCC assays. i These preliminary results support the use of HFn as efficient carrier to enhance mAbs permeation into the brain, without affecting their activity. In Chapter 2, half-chain fragments of cetuximab were conjugated to colloidal NPs (HC-CTX-NPs) to be investigated as surrogates of mAbs in TNBC. Three TNBC cell lines were selected according to EGFR expression and to diverse cetuximab sensitivity. The molecular mechanisms of action of HC-CTX- NPs, including cell targeting, interference with signaling pathways, proliferation, cell cycle, apoptosis and ADCC response, were investigated in TNBC cells. We found that HC-CTX-NPs were able to enhance the therapeutic efficacy and improve the target selectivity against sensitive, but unexpectedly also resistant, TNBC cells. Viability assays and signaling transduction modulation suggested that HC-CTX-NPs not only improved the antibody activity but also exerted different mechanisms of action to circumvent CTX resistance. Our results provide robust evidence of the potential of HC-CTX-NPs in the treatment of TNBC, which could improve curative efficiency, reducing dosages in both sensitive and resistant tumors.
Laporte, Jérôme. "Nouveaux anticorps monoclonaux contre les Yersinia pour le diagnostic et l’immunothérapie". Thesis, Paris 11, 2014. http://www.theses.fr/2014PA114834/document.
Texto completoThree bacteria of the genus Yersinia are pathogenic for the human: Yersinia pestis (the plague bacillus) and the enteropathogenic bacteria: Yersinia pseudotuberculosis and Yersinia enterocolitica. Yersinia pestis is responsible for more than 20,000 human cases of plague declared to the World Health Organization (WHO) during the ten last years in different areas from Africa, Asia and America. Mistakenly considered today as a disease from the past, on the contrary, the plague is re-emerging. Even if it doesn’t occur as a massive epidemic, it still lays down a challenge to the world for its important severity, its quick spreading, the appearance of antimicrobial resistance and a potential use for terrorism. Under the circumstances, the immunotherapy against Y. pestis could be a good option to treat bubonic and pneumonic plague. One the aims of this thesis was to produce murine monoclonal antibodies against the three proteins of the injectisom (YscF, YscC, LcrV), a key virulence factor of Yersinia. The obtained antibodies were characterized and for certain, the epitopes were identified. Then, in collaboration with Elisabeth Carniel from Institut Pasteur, their therapeutic effect was evaluated in vivo with a bubonic plague model in mice. The antibodies generated against the proteins from the injectisom are now evaluated in a diagnosis test for a fast detection of Y. pestis in different biological samples. Yersinia enterocolitica and Yersinia pseudotuberculosis, the two enteropathogenic Yersinia species for humans, have a worldwide distribution and are among the most frequent agents of human diarrhea in temperate and cold countries. However, research of enteropathogenic Yersinia is not consistently performed in medical laboratories because of their specific growth characteristics, which makes their isolation from the stool samples difficult. Moreover, current procedures for isolation are expensive and time consuming, which leads to underestimation of the incidence of yersiniosis and prescriptions of inappropriate antibiotic treatments. One the aims of this thesis was to produce different murine monoclonal antibodies against the main pathogenic biotypes and serotypes of Y. pseudotuberculosis and Y. enterocolitica for the development of fast, sensitive, specific and easy-to-use immunoassays (ELISA and dipsticks), useful for both human and veterinary diagnosis
Sandin, Linda. "Immunomodulatory Therapy of Solid Tumors : With a Focus on Monoclonal Antibodies". Doctoral thesis, Uppsala universitet, Klinisk immunologi, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-210080.
Texto completoHeitzmann-Daverton, Adèle. "Utilisation d'un anticorps monoclonal anti-Tn en immunothérapie des cancers". Phd thesis, Université René Descartes - Paris V, 2013. http://tel.archives-ouvertes.fr/tel-00923181.
Texto completoFagerqvist, Therese. "Studies of α-synuclein Oligomers-with Relevance to Lewy Body Disorders". Doctoral thesis, Uppsala universitet, Institutionen för folkhälso- och vårdvetenskap, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-204466.
Texto completoLibros sobre el tema "Monoclonal antibody, immunocytokine, immunotherapy"
1960-, Grossbard Michael L., ed. Monoclonal antibody-based therapy of cancer. New York: Dekker, 1998.
Buscar texto completoA, Foon Kenneth y Morgan Alton C, eds. Monoclonal antibody therapy of human cancer. Boston: Nijhoff, 1985.
Buscar texto completoRodriguez, Andrės Felipe. Successful immunotherapy to malignant cells with monoclonal antibody to suppressor T cells. [New Haven: s.n.], 1988.
Buscar texto completoFrost & Sullivan., ed. U.S. monoclonal antibody markets: Manufacturers struggling for regulatory approval. Mountain View, Calif: Frost & Sullivan, 1994.
Buscar texto completo1927-, Baldwin R. W., Byers Vera S y Mann Ronald D. 1928-, eds. Monoclonal antibodies and immunoconjugates. Carnforth, Lancs, UK: Parthenon Pub. Group, 1990.
Buscar texto completoLuiten, Rosalie Margaretha. New chimeric monoclonal antibodies against human carcinomas: IgE and bispecific antibody-mediated therapy. [Leiden: University of Leiden, 1998.
Buscar texto completoGray, Lynn. Dynamic antibody industry, including polyclonals and monoclonals. Norwalk, CT: Business Communications Co., 2002.
Buscar texto completoMagerstadt, Michael. Antibody conjugates and malignant disease. Boca Raton: CRC Press, 1991.
Buscar texto completoW, Baldwin R., Byers Vera S y Mann R. D. 1928-, eds. Monoclonal antibodies and immunoconjugates in cancer treatment. Carnforth: Parthenon Publishing, 1990.
Buscar texto completoRotheim, Philip. The dynamic antibody industry, including polyclonals and monoclonals. Norwalk, CT: Business Communications Co., 1992.
Buscar texto completoCapítulos de libros sobre el tema "Monoclonal antibody, immunocytokine, immunotherapy"
Mittendorf, Elizabeth A. y Sabitha Prabhakaran. "Monoclonal Antibody Therapy". En Immunotherapy in Translational Cancer Research, 12–23. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781118684535.ch2.
Texto completoBorghaei, Hossein, Matthew K. Robinson y Louis M. Weiner. "Monoclonal Antibody Therapy of Cancer". En Immunotherapy of Cancer, 487–502. Totowa, NJ: Humana Press, 2006. http://dx.doi.org/10.1385/1-59745-011-1:487.
Texto completoGray, Juliet C. y Paul M. Sondel. "Overview of Monoclonal Antibody Therapies". En Immunotherapy for Pediatric Malignancies, 65–78. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-43486-5_4.
Texto completoRader, Christoph. "Monoclonal Antibody Therapy for Cancer". En Experimental and Applied Immunotherapy, 59–83. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-980-2_3.
Texto completoHamblin, T. J. "Modifications of Monoclonal Antibody for Immunotherapy". En Immunotherapy of Disease, 143–66. Dordrecht: Springer Netherlands, 1989. http://dx.doi.org/10.1007/978-94-009-1844-3_7.
Texto completoPescovitz, Mark D. "Rituximab, an Anti-CD20 Monoclonal Antibody". En Immunotherapy in Transplantation, 362–77. Oxford, UK: Wiley-Blackwell, 2012. http://dx.doi.org/10.1002/9781444355628.ch24.
Texto completoEmbleton, M. J. y R. W. Baldwin. "MONOCLONAL ANTIBODY TARGETING FOR CANCER IMMUNOTHERAPY". En Proceedings of the Third Symposium, Lyon, France, June 26–28, 1985, editado por Jacques Bienvenu, J. A. Grimaud y Philippe Laurent, 529–42. Berlin, Boston: De Gruyter, 1986. http://dx.doi.org/10.1515/9783110860757-066.
Texto completoGouda, Gayatri, Manoj Kumar Gupta, Ravindra Donde, Lambodar Behera y Ramakrishna Vadde. "Monoclonal Antibody Therapy Against Gastrointestinal Tract Cancers". En Immunotherapy for Gastrointestinal Malignancies, 97–111. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-6487-1_7.
Texto completoReisfeld, R. A. "Immunotherapy of Melanoma with Monoclonal Antibody-Drug Conjugates". En Human Melanoma, 399–412. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74496-9_28.
Texto completoMasuho, Yasuhiko, Yoh-Ichi Matsumoto, Tohru Sugano, Takami Tomiyama, Satoshi Sasaki y Tamotsu Koyama. "Development of a Human Monoclonal Antibody against Cytomegalovirus with the Aim of a Passive Immunotherapy". En Therapeutic Monoclonal Antibodies, 187–207. London: Palgrave Macmillan UK, 1990. http://dx.doi.org/10.1007/978-1-349-11894-6_12.
Texto completoActas de conferencias sobre el tema "Monoclonal antibody, immunocytokine, immunotherapy"
Lin, Haishan y Richard Zhang. "Abstract B73: Development of anti-human CLDN18.2 monoclonal antibody as cancer therapeutics". En Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy; November 27-30, 2018; Miami Beach, FL. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/2326-6074.tumimm18-b73.
Texto completoAlrishedan, NS, W. Bodmer, V. Liebe lastun, V. Golubovskaya, J. Wu, A. Bransi, P. Umana, C. Klein y R. Mateus Seidl. "P01.01 PLAP as target for cancer immunotherapy – development and preclinical characterization of bispecific monoclonal antibody in colorectal cancer immunotherapy". En iTOC9 – 9th Immunotherapy of Cancer Conference, September 22–24, 2022 – Munich, Germany. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-itoc9.13.
Texto completoMick, Rosemarie, David Bajor, Lee Richman y Robert Vonderheide. "Abstract A10: Soluble CD25 and C-reactive protein predict overall survival in melanoma patients receiving anti-CD40 monoclonal antibody CP-870,893 (αCD40) and anti-CTLA4 monoclonal antibody tremelimumab". En Abstracts: AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/2326-6074.tumimm14-a10.
Texto completoWelt, Rachel S., Jonathan A. Welt, Virginia Raymond, David Kostyal y Sydney Welt. "Abstract PO020: Anti-membrane-IgM monoclonal antibody, mAb4, inhibits the BCRC, modulating downstream signaling pathways". En Abstracts: AACR Virtual Special Conference: Tumor Immunology and Immunotherapy; October 19-20, 2020. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/2326-6074.tumimm20-po020.
Texto completoKim, Haemi, Kyoung-Jin Kim, Myeong Jin Yoon, Jenny Choih, Eun Ji Cho, Hak-Jun Jung, Kwanghyun Lee et al. "488 GNUV201, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer immunotherapy". En SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.0488.
Texto completoSalameh, Ahmad, Jerri Caldeira, Valeria Rolih, Elisabetta Bolli, Laura Conti y Michael Perrine. "Abstract B37: Development of a monoclonal antibody targeting xCT/SLC7A11 expressed in metastatic cancer cells". En Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy; November 17-20, 2019; Boston, MA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/2326-6074.tumimm19-b37.
Texto completoMacedo, Luciana F., Elizabeth Kaiser, Haiyan Jiang, Hillary Millar, Diana Wiley, Adam Cotty, Fred Kaplan et al. "Abstract A190: Colon tumor cells expressing CD24 have oncogenic properties and are inhibited by monoclonal antibody immunotherapy." En Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-a190.
Texto completoMitsunaga, Makoto, Mikako Ogawa, Nobuyuki Kosaka, Peter L. Choyke y Hisataka Kobayashi. "Abstract 3618: Target-specific photo-activatable immunotherapy (PIT) for cancer based on a monoclonal antibody-photosensitizer conjugate". En Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-3618.
Texto completoStecha, Pete, Denise Garvin, Julia Gilden, Jun Wang, Jamison Grailer, Jim Hartnett, Vanessa Ott, Frank Fan, Mei Cong y Zhijie Jey Cheng. "Abstract 5658: A homogenous PBMC ADCC bioassay enables bridging studies with ADCC reporter bioassays in immunotherapy monoclonal antibody development". En Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-5658.
Texto completoStecha, Pete, Denise Garvin, Julia Gilden, Jun Wang, Jamison Grailer, Jim Hartnett, Gopal B. Krishnan, Frank Fan, Mei Cong y Zhijie Jey Cheng. "Abstract 506: A homogenous PBMC ADCC bioassay enables bridging studies with ADCC reporter bioassays in immunotherapy monoclonal antibody development". En Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-506.
Texto completo